One question belongs in every software-enabled healthcare diligence this quarter.
Not the value proposition. Not the pilot results. The billing code. Which specific HCPCS code does this product get paid under today, what is the payment vehicle, and what do the CY 2027 rules do to it?
The quality of that answer separates management teams who understand their market from teams who understand their product. It is a distinction that used to be survivable and increasingly is not.
Two reimbursement shortcuts closed in July 2026. Breakthrough device designation as a route to a Medicare add-on payment is being eliminated for FY 2028 applications — substantial clinical improvement becomes the single standard. And outsourced clinical labor as a route to remote monitoring revenue is under a proposal that would require direct employment. Any portfolio model still resting on either is carrying an assumption that has expired.
If the answer to “name the code” is that no separately payable code exists, that is not a dealbreaker. It is a valuation input, and it is better discovered in diligence than in the year after close.